Nabil G. Seidah

Dr. Nabil G. Seidah

Montreal Clinical Research Institute
+1
orcid

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2003 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MAMarianne Abifadel
Marianne Abifadel
MVMathilde Varret
Mathilde Varret
JRJean-Pierre H. Rabès
Jean-Pierre H. Rabès
DADelphine Allard
Delphine Allard
KOKhadija Ouguerram
Khadija Ouguerram
CBCatherine Boileau
Catherine Boileau

1 April 2020 in Antiviral Research
Verified
Journal Article
Closed access
BCB. Coutard
B. Coutard
CVcoralie Valle
coralie Valle
XLX. de Lamballerie
X. de Lamballerie
BCB. Canard
B. Canard
NSNabil G. Seidah
Nabil G. Seidah
EDEtienne Decroly
Etienne Decroly

22 August 2005 in Virology Journal
Verified
Journal Article
Open access
MVMartin J Vincent
Martin J Vincent
EBEric Bergeron
Eric Bergeron
SBSuzanne Benjannet
Suzanne Benjannet
BEBobbie R Erickson
Bobbie R Erickson
PRPierre E Rollin
Pierre E Rollin
SNStuart T Nichol
Stuart T Nichol
Background: Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available. Results: We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations. Conclusion: Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.

27 January 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NSNabil G. Seidah
Nabil G. Seidah
SBSuzanne Benjannet
Suzanne Benjannet
LWLouise Wickham
Louise Wickham
JMJadwiga Marcinkiewicz
Jadwiga Marcinkiewicz
SJStéphanie Bélanger Jasmin
Stéphanie Bélanger Jasmin
MCMichel Chrétien
Michel Chrétien
Seven secretory mammalian kexin-like subtilases have been identified that cleave a variety of precursor proteins at monobasic and dibasic residues. The recently characterized pyrolysin-like subtilase SKI-1 cleaves proproteins at nonbasic residues. In this work we describe the properties of a proteinase K-like subtilase, neural apoptosis-regulated convertase 1 (NARC-1), representing the ninth member of the secretory subtilase family. Biosynthetic and microsequencing analyses of WT and mutant enzyme revealed that human and mouse pro-NARC-1 are autocatalytically and intramolecularly processed into NARC-1 at the ( Y , I )V V (V,L)( L , M )↓ motif, a site that is representative of its enzymic specificity. In vitro peptide processing studies and/or Ala substitutions of the P1–P5 sites suggested that hydrophobic/aliphatic residues are more critical at P1, P3, and P5 than at P2 or P4. NARC-1 expression is highest in neuroepithelioma SK-N-MCIXC, hepatic BRL-3A, and in colon carcinoma LoVo-C5 cell lines. In situ hybridization and Northern blot analyses of NARC-1 expression during development in the adult and after partial hepatectomy revealed that it is expressed in cells that have the capacity to proliferate and differentiate. These include hepatocytes, kidney mesenchymal cells, intestinal ileum, and colon epithelia as well as embryonic brain telencephalon neurons. Accordingly, transfection of NARC-1 in primary cultures of embryonic day 13.5 telencephalon cells led to enhanced recruitment of undifferentiated neural progenitor cells into the neuronal lineage, suggesting that NARC-1 is implicated in the differentiation of cortical neurons.

12 December 2012 in Nature
Verified
Journal Article
Open access
PDF file
JBJérémy Besnard
Jérémy Besnard
GRGian Filippo Ruda
Gian Filippo Ruda
VSVincent Setola
Vincent Setola
KAKeren Abecassis
Keren Abecassis
RRRamona M. Rodriguiz
Ramona M. Rodriguiz
AHAndrew L. Hopkins
Andrew L. Hopkins
The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligand–target predictions of prospectively designed ligands were tested experimentally, of which 75% were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.

20 April 2012 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
NSNabil G. Seidah
Nabil G. Seidah
APAnnik Prat
Annik Prat